Amicus Therapeutics Reports Q3 Earnings, Revenues Up 19% YoY

Amicus Therapeutics reported Q3 earnings of 17 cents per share, beating the Zacks Consensus Estimate of 12 cents. Revenues totaled $169.1 million, up 19% YoY and beating the estimate of $165 million. The growth was driven by higher sales of Galafold and the newly approved combo drug, Pombiliti + Opfolda. The company maintained its financial guidance for 2025, expecting total revenues to grow 15-22% at CER and achieving positive GAAP net income in H2 2025.